Immunomodulatory placental-expanded, mesenchymal stromal cells improve muscle function following hip arthroplasty. [15] |
Randomized, double blind, and placebo-controlled, phase I/IIa study |
20 |
Skeletal muscle injury – hip arthroplasty model |
Winkler, (2018) |
Safety and efficacy of allogenic placental mesenchymal stem cells for treating knee osteoarthritis: a pilot study. [17] |
Randomized, controlled, double-blind clinical trial |
20 |
Knee osteoarthritis |
Soltani, (2018) |
Determining the feasibility of managing erectile dysfunction in humans with placental-derived stem cells. [20] |
Prospective, non-controlled, phase I clinical trial |
8 |
Erectile dysfunction |
Levy, (2016) |
Placenta-derived mesenchymal-like cells (PDA-001) as therapy for chronic pulmonary sarcoidosis: a phase 1 study. [23] |
Prospective, non-controlled, single-center, open-label phase I trial |
4 |
Chronic pulmonary sarcoidosis |
Baughman, (2015) |
A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis. [24] |
Single center, non-randomized, dose escalation phase Ib trial |
8 |
Idiopathic pulmonary fibrosis |
Chambers, (2014) |
Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study. [28] |
Prospective, non-controlled, phase I clinical trial |
10 |
Type 2 diabetes |
Jiang, (2011) |
Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study. [31] |
Multicenter, randomized, double-blind, placebo-controlled, 2-dose ranging, phase Ib study |
16 |
Multiple sclerosis |
Lublin, (2014) |
Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1/2 randomized controlled trial (rimecard trial [randomized clinical trial of intravenous infusion umbilical cord mesenchymal stem cells on cardiopathy]). [34] |
Randomized, controlled trial, Phase I/II |
30 |
Chronic stable heart failure and reduced ejection fraction |
Bartolucci, (2017) |
Effect of intramyocardial grafting collagen scaffold with mesenchymal stromal cells in patients with chronic ischemic heart disease: a randomized clinical trial.[35] |
Randomized, double-blind clinical trial |
50 |
Chronic ischemic heart disease |
He, (2020) |
Umbilical cord-derived mesenchymal stromal cells (MSCs) for knee osteoarthritis: repeated MSC dosing is superior to a single MSC dose and to hyaluronic acid in a controlled randomized phase I/II trial. [36] |
Randomized, controlled, phase I/II trial |
26 |
Knee osteoarthritis |
Matas, (2019) |
Efficacy and safety of umbilical cord mesenchymal stem cell therapy for rheumatoid arthritis patients: a prospective phase I/II study. [38] |
Prospective phase I/II study |
64 |
Rheumatoid arthritis |
Wang, (2019) |
Umbilical cord mesenchymal stem cell treatment for Crohn’s disease: a randomized controlled clinical trial. [41] |
Randomized controlled clinical trial |
82 |
Crohn’s disease |
Zhang, (2018) |
Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis. [42] |
Open-label, single-arm, single-center phase I/ II trial |
20 |
Multiple sclerosis |
Riordan, (2018) |
Allogeneic mesenchymal stem cells as induction therapy are safe and feasible in renal allografts: pilot results of a multicenter randomized controlled trial. [43] |
Multicenter randomized controlled trial |
42 |
Renal transplantation |
Sun, (2018) |
A pilot study of mesenchymal stem cell therapy for acute liver allograft rejection. [44] |
Randomized, controlled trial |
27 |
Acute liver allograft rejection |
Shi, (2017) |
Allogeneic cell therapy using umbilical cord MSCs on collagen scaffolds for patients with recurrent uterine adhesion: a phase I clinical trial. [45] |
Prospective, non-controlled, phase I clinical trial |
26 |
Infertility caused by recurrent intrauterine adhesions |
Cao, (2018) |
Umbilical cord-derived mesenchymal stem (stromal) cells for treatment of severe sepsis: aphase 1 clinical trial. [47] |
Single-center, open-label, dose-escalation phase I clinical trial |
15 |
Severe sepsis |
He, (2018) |
Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. [48] |
Parallel assigned controlled, non-randomized, phase I clinical trial |
18 |
COVID-19 |
Meng, (2020) |
Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. [49] |
Single-center open-label, individually randomized, standard treatment-controlled trial |
41 |
COVID-19 |
Shu, (2020) |